In conclusion, humanized CD19 CAR-T cell therapy provided a treatment option for CD19-positive B-ALL patients who relapsed after or resisted prior murine CD19 CAR-T, hCD19 CAR-T followed by allo-transplantation allowed CR patients to obtain a longer event-free remission. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.